Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer

Joshua P. Raff, Lakshmi Rajdev, Umekalsoom Malik, Yelena Novik, Jane M. Manalo, Abdissa Negassa, Una Hopkins, Catherine Sarta, Joseph A. Sparano

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

This study was designed to determine the efficacy and toxicity of weekly docetaxel in metastatic breast cancer when given alone (for HER2/neu-negative disease) or with trastuzumab (for HER2/neu-overexpressing disease). Patients with metastatic breast carcinoma received docetaxel given on 2 different schedules (group 1A, 33 mg/m2 weekly [n = 21]; group 1B, 40 mg/m2 weekly for 3 weeks with 1 week off [n = 14]. Patients with HER2/neu-overexpressing disease also received trastuzumab 4 mg/kg on day 1, then 2 mg/kg on days 8 and 15 of each 28-day cycle (group 2). Fifty-two patients were treated with docetaxel alone (group 1A/B, n = 35 or in combination with trastuzumab (group 2, n = 17). Prior taxane therapy given every 3 weeks had been used for metastatic disease in 19 of 35 patients (54%) in group 1A/B in 2 of 17 patients (12%) in group 2. The mean delivered dose intensity of docetaxel was 29 mg/m2 per week. Partial response occurred in 7 of 35 patients (21%; 95% exact binomial confidence interval [CI], 9%-38%) treated with docetaxel alone, including 3 of 19 taxane-pretreated patient (16%) and 4 of 16 taxane-naive patients (25%). Partial response occurred in 10 of 17 patients (59%; 95% CI, 34%-82%) treated with docetaxel/trastuzumab. The most common grade 3/4 toxicities, occurring in ≥ 10% patients, included neutropenia (21%), pulmonary toxicity (12%), and hyperglycemia (10%). The median times to disease progression were 4.5 months (95% CI, 2.5-6.5 months) in the docetaxel group and 8.5 months (95% CI, 4.5-12.5 months) in the docetaxel/trastuzumab group. Weekly docetaxel/trastuzumab is an affective regimen for patients with HER2/neu-overexpressing metastatic breast cancer. Weekly docetaxel may be effective in as many as 20% of patients who had progressive disease after treatment with taxanes given every 3 weeks.

Original languageEnglish (US)
Pages (from-to)420-427
Number of pages8
JournalClinical Breast Cancer
Volume4
Issue number6
StatePublished - 2004

Fingerprint

docetaxel
Breast Neoplasms
Confidence Intervals
Trastuzumab

Keywords

  • Chronic heart failure
  • Epiphora
  • Fatigue
  • Onycholysis
  • Taxanes

ASJC Scopus subject areas

  • Cancer Research

Cite this

Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. / Raff, Joshua P.; Rajdev, Lakshmi; Malik, Umekalsoom; Novik, Yelena; Manalo, Jane M.; Negassa, Abdissa; Hopkins, Una; Sarta, Catherine; Sparano, Joseph A.

In: Clinical Breast Cancer, Vol. 4, No. 6, 2004, p. 420-427.

Research output: Contribution to journalArticle

Raff, Joshua P. ; Rajdev, Lakshmi ; Malik, Umekalsoom ; Novik, Yelena ; Manalo, Jane M. ; Negassa, Abdissa ; Hopkins, Una ; Sarta, Catherine ; Sparano, Joseph A. / Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. In: Clinical Breast Cancer. 2004 ; Vol. 4, No. 6. pp. 420-427.
@article{d5926d8a5dd941f3851ea96ad52d2b78,
title = "Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer",
abstract = "This study was designed to determine the efficacy and toxicity of weekly docetaxel in metastatic breast cancer when given alone (for HER2/neu-negative disease) or with trastuzumab (for HER2/neu-overexpressing disease). Patients with metastatic breast carcinoma received docetaxel given on 2 different schedules (group 1A, 33 mg/m2 weekly [n = 21]; group 1B, 40 mg/m2 weekly for 3 weeks with 1 week off [n = 14]. Patients with HER2/neu-overexpressing disease also received trastuzumab 4 mg/kg on day 1, then 2 mg/kg on days 8 and 15 of each 28-day cycle (group 2). Fifty-two patients were treated with docetaxel alone (group 1A/B, n = 35 or in combination with trastuzumab (group 2, n = 17). Prior taxane therapy given every 3 weeks had been used for metastatic disease in 19 of 35 patients (54{\%}) in group 1A/B in 2 of 17 patients (12{\%}) in group 2. The mean delivered dose intensity of docetaxel was 29 mg/m2 per week. Partial response occurred in 7 of 35 patients (21{\%}; 95{\%} exact binomial confidence interval [CI], 9{\%}-38{\%}) treated with docetaxel alone, including 3 of 19 taxane-pretreated patient (16{\%}) and 4 of 16 taxane-naive patients (25{\%}). Partial response occurred in 10 of 17 patients (59{\%}; 95{\%} CI, 34{\%}-82{\%}) treated with docetaxel/trastuzumab. The most common grade 3/4 toxicities, occurring in ≥ 10{\%} patients, included neutropenia (21{\%}), pulmonary toxicity (12{\%}), and hyperglycemia (10{\%}). The median times to disease progression were 4.5 months (95{\%} CI, 2.5-6.5 months) in the docetaxel group and 8.5 months (95{\%} CI, 4.5-12.5 months) in the docetaxel/trastuzumab group. Weekly docetaxel/trastuzumab is an affective regimen for patients with HER2/neu-overexpressing metastatic breast cancer. Weekly docetaxel may be effective in as many as 20{\%} of patients who had progressive disease after treatment with taxanes given every 3 weeks.",
keywords = "Chronic heart failure, Epiphora, Fatigue, Onycholysis, Taxanes",
author = "Raff, {Joshua P.} and Lakshmi Rajdev and Umekalsoom Malik and Yelena Novik and Manalo, {Jane M.} and Abdissa Negassa and Una Hopkins and Catherine Sarta and Sparano, {Joseph A.}",
year = "2004",
language = "English (US)",
volume = "4",
pages = "420--427",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer

AU - Raff, Joshua P.

AU - Rajdev, Lakshmi

AU - Malik, Umekalsoom

AU - Novik, Yelena

AU - Manalo, Jane M.

AU - Negassa, Abdissa

AU - Hopkins, Una

AU - Sarta, Catherine

AU - Sparano, Joseph A.

PY - 2004

Y1 - 2004

N2 - This study was designed to determine the efficacy and toxicity of weekly docetaxel in metastatic breast cancer when given alone (for HER2/neu-negative disease) or with trastuzumab (for HER2/neu-overexpressing disease). Patients with metastatic breast carcinoma received docetaxel given on 2 different schedules (group 1A, 33 mg/m2 weekly [n = 21]; group 1B, 40 mg/m2 weekly for 3 weeks with 1 week off [n = 14]. Patients with HER2/neu-overexpressing disease also received trastuzumab 4 mg/kg on day 1, then 2 mg/kg on days 8 and 15 of each 28-day cycle (group 2). Fifty-two patients were treated with docetaxel alone (group 1A/B, n = 35 or in combination with trastuzumab (group 2, n = 17). Prior taxane therapy given every 3 weeks had been used for metastatic disease in 19 of 35 patients (54%) in group 1A/B in 2 of 17 patients (12%) in group 2. The mean delivered dose intensity of docetaxel was 29 mg/m2 per week. Partial response occurred in 7 of 35 patients (21%; 95% exact binomial confidence interval [CI], 9%-38%) treated with docetaxel alone, including 3 of 19 taxane-pretreated patient (16%) and 4 of 16 taxane-naive patients (25%). Partial response occurred in 10 of 17 patients (59%; 95% CI, 34%-82%) treated with docetaxel/trastuzumab. The most common grade 3/4 toxicities, occurring in ≥ 10% patients, included neutropenia (21%), pulmonary toxicity (12%), and hyperglycemia (10%). The median times to disease progression were 4.5 months (95% CI, 2.5-6.5 months) in the docetaxel group and 8.5 months (95% CI, 4.5-12.5 months) in the docetaxel/trastuzumab group. Weekly docetaxel/trastuzumab is an affective regimen for patients with HER2/neu-overexpressing metastatic breast cancer. Weekly docetaxel may be effective in as many as 20% of patients who had progressive disease after treatment with taxanes given every 3 weeks.

AB - This study was designed to determine the efficacy and toxicity of weekly docetaxel in metastatic breast cancer when given alone (for HER2/neu-negative disease) or with trastuzumab (for HER2/neu-overexpressing disease). Patients with metastatic breast carcinoma received docetaxel given on 2 different schedules (group 1A, 33 mg/m2 weekly [n = 21]; group 1B, 40 mg/m2 weekly for 3 weeks with 1 week off [n = 14]. Patients with HER2/neu-overexpressing disease also received trastuzumab 4 mg/kg on day 1, then 2 mg/kg on days 8 and 15 of each 28-day cycle (group 2). Fifty-two patients were treated with docetaxel alone (group 1A/B, n = 35 or in combination with trastuzumab (group 2, n = 17). Prior taxane therapy given every 3 weeks had been used for metastatic disease in 19 of 35 patients (54%) in group 1A/B in 2 of 17 patients (12%) in group 2. The mean delivered dose intensity of docetaxel was 29 mg/m2 per week. Partial response occurred in 7 of 35 patients (21%; 95% exact binomial confidence interval [CI], 9%-38%) treated with docetaxel alone, including 3 of 19 taxane-pretreated patient (16%) and 4 of 16 taxane-naive patients (25%). Partial response occurred in 10 of 17 patients (59%; 95% CI, 34%-82%) treated with docetaxel/trastuzumab. The most common grade 3/4 toxicities, occurring in ≥ 10% patients, included neutropenia (21%), pulmonary toxicity (12%), and hyperglycemia (10%). The median times to disease progression were 4.5 months (95% CI, 2.5-6.5 months) in the docetaxel group and 8.5 months (95% CI, 4.5-12.5 months) in the docetaxel/trastuzumab group. Weekly docetaxel/trastuzumab is an affective regimen for patients with HER2/neu-overexpressing metastatic breast cancer. Weekly docetaxel may be effective in as many as 20% of patients who had progressive disease after treatment with taxanes given every 3 weeks.

KW - Chronic heart failure

KW - Epiphora

KW - Fatigue

KW - Onycholysis

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=1842530214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842530214&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 420

EP - 427

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -